Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT
Autologous hematopoietic cell transplantation (auto-HCT) may be performed in multiple myeloma (MM) patients relapsing after a previous auto-HCT. For those without an adequate dose of stored stem cells, remobilization is necessary. This retrospective study included patients who, following disease rel...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2022-04, Vol.57 (4), p.633-640 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 640 |
|---|---|
| container_issue | 4 |
| container_start_page | 633 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 57 |
| creator | Drozd-Sokołowska, Joanna Gras, Luuk Zinger, Nienke Snowden, John A. Arat, Mutlu Basak, Grzegorz Pouli, Anastasia Crawley, Charles Wilson, Keith M. O. Tilly, Herve Byrne, Jennifer Bulabois, Claude Eric Passweg, Jakob Ozkurt, Zubeyde Nur Schroyens, Wilfried Lioure, Bruno Colorado Araujo, Mercedes Poiré, Xavier Van Gorkom, Gwendolyn Gurman, Gunhan de Wreede, Liesbeth C. Hayden, Patrick J. Beksac, Meral Schönland, Stefan O. Yakoub-Agha, Ibrahim |
| description | Autologous hematopoietic cell transplantation (auto-HCT) may be performed in multiple myeloma (MM) patients relapsing after a previous auto-HCT. For those without an adequate dose of stored stem cells, remobilization is necessary. This retrospective study included patients who, following disease relapse after the first auto-HCT(s), underwent stem cell remobilization and auto-HCT performed using these cells. There were 305 patients, 68% male, median age at salvage auto-HCT was 59 years. The median time to relapse after the first-line penultimate auto-HCT(s) was 30.6 months, the median follow-up after salvage auto-HCT 31 months. The 2- and 4-year non-relapse mortality (NRM) after the salvage auto-HCT was 5 and 9%, the relapse incidence 56 and 76%, respectively. Overall survival (OS) after 2 and 4 years was 76 and 52%, progression-free survival (PFS) 39 and 15%. In multivariable analysis an increasing interval between the penultimate auto-HCT and relapse was associated with better OS and PFS, later calendar year of salvage auto-HCT with better OS. In conclusion, salvage auto-HCT performed with cells remobilized after a previous auto-HCT was associated with acceptable NRM. The leading cause of failure was disease progression of MM, which correlated with a shorter interval from the penultimate auto-HCT to the first relapse. |
| doi_str_mv | 10.1038/s41409-022-01592-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8993690</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2629380008</sourcerecordid><originalsourceid>FETCH-LOGICAL-c508t-85a6ae0adf7d75458857932d127dee08bef6bd9e9b65b83c39243df9c9f196d73</originalsourceid><addsrcrecordid>eNp9kstu1DAUhiMEokPhBVggS2xgEfAlduwN0nRUKNJUsChiaTnJySRVEgfbGTQ73oH34KF4EpymFJgFqyP7fOc_F_1J8pTgVwQz-dpnJMMqxZSmmHBF08O9ZEWyXKScCX4_WWEqZMqYUCfJI--vMSZZhvnD5IRxIhSV2Sr5sZ6C7ezOTh410JtgR9tCaEtUQteh4Mzgx84MwYTWDqi2DjnozOihQv3UhXbsAPUH6Gxv0AguAn1MfW1Dc6Pg0ehsObn4Z-oALj5h387djqR_fvvuw1QdUOxSQGO6GtkabS4_f5xjaACdn11ePU4e1Kbz8OQ2niaf3p5fbS7S7Yd37zfrbVpyLEMquREGsKnqvMp5xqXkuWK0IjSvALAsoBZFpUAVgheSlUzRjFW1KlVNlKhydpq8WXTHqYj7lDDEcTs9urY37qCtafW_maFt9M7utVQq3htHgZeLQHNUdrHe6vkPZ5woRsSeRPbFbTNnv0zgg-5bPx_PDBAvpamgikmMsYzo8yP02k5uiKeIVCYZFYzNFF2o0lnvHdR3ExCsZ-voxTo6WkffWEcfYtGzv1e-K_ntlQiwBfAxNezA_en9H9lfEi3Vmw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2648326338</pqid></control><display><type>article</type><title>Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SpringerLink Journals - AutoHoldings</source><creator>Drozd-Sokołowska, Joanna ; Gras, Luuk ; Zinger, Nienke ; Snowden, John A. ; Arat, Mutlu ; Basak, Grzegorz ; Pouli, Anastasia ; Crawley, Charles ; Wilson, Keith M. O. ; Tilly, Herve ; Byrne, Jennifer ; Bulabois, Claude Eric ; Passweg, Jakob ; Ozkurt, Zubeyde Nur ; Schroyens, Wilfried ; Lioure, Bruno ; Colorado Araujo, Mercedes ; Poiré, Xavier ; Van Gorkom, Gwendolyn ; Gurman, Gunhan ; de Wreede, Liesbeth C. ; Hayden, Patrick J. ; Beksac, Meral ; Schönland, Stefan O. ; Yakoub-Agha, Ibrahim</creator><creatorcontrib>Drozd-Sokołowska, Joanna ; Gras, Luuk ; Zinger, Nienke ; Snowden, John A. ; Arat, Mutlu ; Basak, Grzegorz ; Pouli, Anastasia ; Crawley, Charles ; Wilson, Keith M. O. ; Tilly, Herve ; Byrne, Jennifer ; Bulabois, Claude Eric ; Passweg, Jakob ; Ozkurt, Zubeyde Nur ; Schroyens, Wilfried ; Lioure, Bruno ; Colorado Araujo, Mercedes ; Poiré, Xavier ; Van Gorkom, Gwendolyn ; Gurman, Gunhan ; de Wreede, Liesbeth C. ; Hayden, Patrick J. ; Beksac, Meral ; Schönland, Stefan O. ; Yakoub-Agha, Ibrahim</creatorcontrib><description>Autologous hematopoietic cell transplantation (auto-HCT) may be performed in multiple myeloma (MM) patients relapsing after a previous auto-HCT. For those without an adequate dose of stored stem cells, remobilization is necessary. This retrospective study included patients who, following disease relapse after the first auto-HCT(s), underwent stem cell remobilization and auto-HCT performed using these cells. There were 305 patients, 68% male, median age at salvage auto-HCT was 59 years. The median time to relapse after the first-line penultimate auto-HCT(s) was 30.6 months, the median follow-up after salvage auto-HCT 31 months. The 2- and 4-year non-relapse mortality (NRM) after the salvage auto-HCT was 5 and 9%, the relapse incidence 56 and 76%, respectively. Overall survival (OS) after 2 and 4 years was 76 and 52%, progression-free survival (PFS) 39 and 15%. In multivariable analysis an increasing interval between the penultimate auto-HCT and relapse was associated with better OS and PFS, later calendar year of salvage auto-HCT with better OS. In conclusion, salvage auto-HCT performed with cells remobilized after a previous auto-HCT was associated with acceptable NRM. The leading cause of failure was disease progression of MM, which correlated with a shorter interval from the penultimate auto-HCT to the first relapse.</description><identifier>ISSN: 0268-3369</identifier><identifier>ISSN: 1476-5365</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/s41409-022-01592-y</identifier><identifier>PMID: 35169284</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13/100 ; 631/67/1990/804 ; 692/308/2171 ; 82/1 ; Autografts ; Cell Biology ; Female ; Hematology ; Hematopoietic Stem Cell Transplantation ; Humans ; Internal Medicine ; Life Sciences ; Male ; Medicine ; Medicine & Public Health ; Multiple myeloma ; Multiple Myeloma - therapy ; Neoplasm Recurrence, Local ; Public Health ; Retrospective Studies ; Stem cell transplantation ; Stem Cells ; Survival ; Transplantation ; Transplantation, Autologous ; Treatment Outcome</subject><ispartof>Bone marrow transplantation (Basingstoke), 2022-04, Vol.57 (4), p.633-640</ispartof><rights>The Author(s) 2022</rights><rights>2022. The Author(s).</rights><rights>The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Attribution</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c508t-85a6ae0adf7d75458857932d127dee08bef6bd9e9b65b83c39243df9c9f196d73</citedby><cites>FETCH-LOGICAL-c508t-85a6ae0adf7d75458857932d127dee08bef6bd9e9b65b83c39243df9c9f196d73</cites><orcidid>0000-0002-4853-5579 ; 0000-0001-6819-3476 ; 0000-0003-1897-0227 ; 0000-0003-2039-8557 ; 0000-0003-3858-8180 ; 0000-0003-1374-4503 ; 0000-0003-4524-8782</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41409-022-01592-y$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41409-022-01592-y$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35169284$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.univ-lille.fr/hal-04519316$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Drozd-Sokołowska, Joanna</creatorcontrib><creatorcontrib>Gras, Luuk</creatorcontrib><creatorcontrib>Zinger, Nienke</creatorcontrib><creatorcontrib>Snowden, John A.</creatorcontrib><creatorcontrib>Arat, Mutlu</creatorcontrib><creatorcontrib>Basak, Grzegorz</creatorcontrib><creatorcontrib>Pouli, Anastasia</creatorcontrib><creatorcontrib>Crawley, Charles</creatorcontrib><creatorcontrib>Wilson, Keith M. O.</creatorcontrib><creatorcontrib>Tilly, Herve</creatorcontrib><creatorcontrib>Byrne, Jennifer</creatorcontrib><creatorcontrib>Bulabois, Claude Eric</creatorcontrib><creatorcontrib>Passweg, Jakob</creatorcontrib><creatorcontrib>Ozkurt, Zubeyde Nur</creatorcontrib><creatorcontrib>Schroyens, Wilfried</creatorcontrib><creatorcontrib>Lioure, Bruno</creatorcontrib><creatorcontrib>Colorado Araujo, Mercedes</creatorcontrib><creatorcontrib>Poiré, Xavier</creatorcontrib><creatorcontrib>Van Gorkom, Gwendolyn</creatorcontrib><creatorcontrib>Gurman, Gunhan</creatorcontrib><creatorcontrib>de Wreede, Liesbeth C.</creatorcontrib><creatorcontrib>Hayden, Patrick J.</creatorcontrib><creatorcontrib>Beksac, Meral</creatorcontrib><creatorcontrib>Schönland, Stefan O.</creatorcontrib><creatorcontrib>Yakoub-Agha, Ibrahim</creatorcontrib><title>Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><addtitle>Bone Marrow Transplant</addtitle><description>Autologous hematopoietic cell transplantation (auto-HCT) may be performed in multiple myeloma (MM) patients relapsing after a previous auto-HCT. For those without an adequate dose of stored stem cells, remobilization is necessary. This retrospective study included patients who, following disease relapse after the first auto-HCT(s), underwent stem cell remobilization and auto-HCT performed using these cells. There were 305 patients, 68% male, median age at salvage auto-HCT was 59 years. The median time to relapse after the first-line penultimate auto-HCT(s) was 30.6 months, the median follow-up after salvage auto-HCT 31 months. The 2- and 4-year non-relapse mortality (NRM) after the salvage auto-HCT was 5 and 9%, the relapse incidence 56 and 76%, respectively. Overall survival (OS) after 2 and 4 years was 76 and 52%, progression-free survival (PFS) 39 and 15%. In multivariable analysis an increasing interval between the penultimate auto-HCT and relapse was associated with better OS and PFS, later calendar year of salvage auto-HCT with better OS. In conclusion, salvage auto-HCT performed with cells remobilized after a previous auto-HCT was associated with acceptable NRM. The leading cause of failure was disease progression of MM, which correlated with a shorter interval from the penultimate auto-HCT to the first relapse.</description><subject>13/100</subject><subject>631/67/1990/804</subject><subject>692/308/2171</subject><subject>82/1</subject><subject>Autografts</subject><subject>Cell Biology</subject><subject>Female</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - therapy</subject><subject>Neoplasm Recurrence, Local</subject><subject>Public Health</subject><subject>Retrospective Studies</subject><subject>Stem cell transplantation</subject><subject>Stem Cells</subject><subject>Survival</subject><subject>Transplantation</subject><subject>Transplantation, Autologous</subject><subject>Treatment Outcome</subject><issn>0268-3369</issn><issn>1476-5365</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kstu1DAUhiMEokPhBVggS2xgEfAlduwN0nRUKNJUsChiaTnJySRVEgfbGTQ73oH34KF4EpymFJgFqyP7fOc_F_1J8pTgVwQz-dpnJMMqxZSmmHBF08O9ZEWyXKScCX4_WWEqZMqYUCfJI--vMSZZhvnD5IRxIhSV2Sr5sZ6C7ezOTh410JtgR9tCaEtUQteh4Mzgx84MwYTWDqi2DjnozOihQv3UhXbsAPUH6Gxv0AguAn1MfW1Dc6Pg0ehsObn4Z-oALj5h387djqR_fvvuw1QdUOxSQGO6GtkabS4_f5xjaACdn11ePU4e1Kbz8OQ2niaf3p5fbS7S7Yd37zfrbVpyLEMquREGsKnqvMp5xqXkuWK0IjSvALAsoBZFpUAVgheSlUzRjFW1KlVNlKhydpq8WXTHqYj7lDDEcTs9urY37qCtafW_maFt9M7utVQq3htHgZeLQHNUdrHe6vkPZ5woRsSeRPbFbTNnv0zgg-5bPx_PDBAvpamgikmMsYzo8yP02k5uiKeIVCYZFYzNFF2o0lnvHdR3ExCsZ-voxTo6WkffWEcfYtGzv1e-K_ntlQiwBfAxNezA_en9H9lfEi3Vmw</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Drozd-Sokołowska, Joanna</creator><creator>Gras, Luuk</creator><creator>Zinger, Nienke</creator><creator>Snowden, John A.</creator><creator>Arat, Mutlu</creator><creator>Basak, Grzegorz</creator><creator>Pouli, Anastasia</creator><creator>Crawley, Charles</creator><creator>Wilson, Keith M. O.</creator><creator>Tilly, Herve</creator><creator>Byrne, Jennifer</creator><creator>Bulabois, Claude Eric</creator><creator>Passweg, Jakob</creator><creator>Ozkurt, Zubeyde Nur</creator><creator>Schroyens, Wilfried</creator><creator>Lioure, Bruno</creator><creator>Colorado Araujo, Mercedes</creator><creator>Poiré, Xavier</creator><creator>Van Gorkom, Gwendolyn</creator><creator>Gurman, Gunhan</creator><creator>de Wreede, Liesbeth C.</creator><creator>Hayden, Patrick J.</creator><creator>Beksac, Meral</creator><creator>Schönland, Stefan O.</creator><creator>Yakoub-Agha, Ibrahim</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4853-5579</orcidid><orcidid>https://orcid.org/0000-0001-6819-3476</orcidid><orcidid>https://orcid.org/0000-0003-1897-0227</orcidid><orcidid>https://orcid.org/0000-0003-2039-8557</orcidid><orcidid>https://orcid.org/0000-0003-3858-8180</orcidid><orcidid>https://orcid.org/0000-0003-1374-4503</orcidid><orcidid>https://orcid.org/0000-0003-4524-8782</orcidid></search><sort><creationdate>20220401</creationdate><title>Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT</title><author>Drozd-Sokołowska, Joanna ; Gras, Luuk ; Zinger, Nienke ; Snowden, John A. ; Arat, Mutlu ; Basak, Grzegorz ; Pouli, Anastasia ; Crawley, Charles ; Wilson, Keith M. O. ; Tilly, Herve ; Byrne, Jennifer ; Bulabois, Claude Eric ; Passweg, Jakob ; Ozkurt, Zubeyde Nur ; Schroyens, Wilfried ; Lioure, Bruno ; Colorado Araujo, Mercedes ; Poiré, Xavier ; Van Gorkom, Gwendolyn ; Gurman, Gunhan ; de Wreede, Liesbeth C. ; Hayden, Patrick J. ; Beksac, Meral ; Schönland, Stefan O. ; Yakoub-Agha, Ibrahim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c508t-85a6ae0adf7d75458857932d127dee08bef6bd9e9b65b83c39243df9c9f196d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>13/100</topic><topic>631/67/1990/804</topic><topic>692/308/2171</topic><topic>82/1</topic><topic>Autografts</topic><topic>Cell Biology</topic><topic>Female</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - therapy</topic><topic>Neoplasm Recurrence, Local</topic><topic>Public Health</topic><topic>Retrospective Studies</topic><topic>Stem cell transplantation</topic><topic>Stem Cells</topic><topic>Survival</topic><topic>Transplantation</topic><topic>Transplantation, Autologous</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Drozd-Sokołowska, Joanna</creatorcontrib><creatorcontrib>Gras, Luuk</creatorcontrib><creatorcontrib>Zinger, Nienke</creatorcontrib><creatorcontrib>Snowden, John A.</creatorcontrib><creatorcontrib>Arat, Mutlu</creatorcontrib><creatorcontrib>Basak, Grzegorz</creatorcontrib><creatorcontrib>Pouli, Anastasia</creatorcontrib><creatorcontrib>Crawley, Charles</creatorcontrib><creatorcontrib>Wilson, Keith M. O.</creatorcontrib><creatorcontrib>Tilly, Herve</creatorcontrib><creatorcontrib>Byrne, Jennifer</creatorcontrib><creatorcontrib>Bulabois, Claude Eric</creatorcontrib><creatorcontrib>Passweg, Jakob</creatorcontrib><creatorcontrib>Ozkurt, Zubeyde Nur</creatorcontrib><creatorcontrib>Schroyens, Wilfried</creatorcontrib><creatorcontrib>Lioure, Bruno</creatorcontrib><creatorcontrib>Colorado Araujo, Mercedes</creatorcontrib><creatorcontrib>Poiré, Xavier</creatorcontrib><creatorcontrib>Van Gorkom, Gwendolyn</creatorcontrib><creatorcontrib>Gurman, Gunhan</creatorcontrib><creatorcontrib>de Wreede, Liesbeth C.</creatorcontrib><creatorcontrib>Hayden, Patrick J.</creatorcontrib><creatorcontrib>Beksac, Meral</creatorcontrib><creatorcontrib>Schönland, Stefan O.</creatorcontrib><creatorcontrib>Yakoub-Agha, Ibrahim</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Drozd-Sokołowska, Joanna</au><au>Gras, Luuk</au><au>Zinger, Nienke</au><au>Snowden, John A.</au><au>Arat, Mutlu</au><au>Basak, Grzegorz</au><au>Pouli, Anastasia</au><au>Crawley, Charles</au><au>Wilson, Keith M. O.</au><au>Tilly, Herve</au><au>Byrne, Jennifer</au><au>Bulabois, Claude Eric</au><au>Passweg, Jakob</au><au>Ozkurt, Zubeyde Nur</au><au>Schroyens, Wilfried</au><au>Lioure, Bruno</au><au>Colorado Araujo, Mercedes</au><au>Poiré, Xavier</au><au>Van Gorkom, Gwendolyn</au><au>Gurman, Gunhan</au><au>de Wreede, Liesbeth C.</au><au>Hayden, Patrick J.</au><au>Beksac, Meral</au><au>Schönland, Stefan O.</au><au>Yakoub-Agha, Ibrahim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><stitle>Bone Marrow Transplant</stitle><addtitle>Bone Marrow Transplant</addtitle><date>2022-04-01</date><risdate>2022</risdate><volume>57</volume><issue>4</issue><spage>633</spage><epage>640</epage><pages>633-640</pages><issn>0268-3369</issn><issn>1476-5365</issn><eissn>1476-5365</eissn><abstract>Autologous hematopoietic cell transplantation (auto-HCT) may be performed in multiple myeloma (MM) patients relapsing after a previous auto-HCT. For those without an adequate dose of stored stem cells, remobilization is necessary. This retrospective study included patients who, following disease relapse after the first auto-HCT(s), underwent stem cell remobilization and auto-HCT performed using these cells. There were 305 patients, 68% male, median age at salvage auto-HCT was 59 years. The median time to relapse after the first-line penultimate auto-HCT(s) was 30.6 months, the median follow-up after salvage auto-HCT 31 months. The 2- and 4-year non-relapse mortality (NRM) after the salvage auto-HCT was 5 and 9%, the relapse incidence 56 and 76%, respectively. Overall survival (OS) after 2 and 4 years was 76 and 52%, progression-free survival (PFS) 39 and 15%. In multivariable analysis an increasing interval between the penultimate auto-HCT and relapse was associated with better OS and PFS, later calendar year of salvage auto-HCT with better OS. In conclusion, salvage auto-HCT performed with cells remobilized after a previous auto-HCT was associated with acceptable NRM. The leading cause of failure was disease progression of MM, which correlated with a shorter interval from the penultimate auto-HCT to the first relapse.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>35169284</pmid><doi>10.1038/s41409-022-01592-y</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-4853-5579</orcidid><orcidid>https://orcid.org/0000-0001-6819-3476</orcidid><orcidid>https://orcid.org/0000-0003-1897-0227</orcidid><orcidid>https://orcid.org/0000-0003-2039-8557</orcidid><orcidid>https://orcid.org/0000-0003-3858-8180</orcidid><orcidid>https://orcid.org/0000-0003-1374-4503</orcidid><orcidid>https://orcid.org/0000-0003-4524-8782</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2022-04, Vol.57 (4), p.633-640 |
| issn | 0268-3369 1476-5365 1476-5365 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8993690 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SpringerLink Journals - AutoHoldings |
| subjects | 13/100 631/67/1990/804 692/308/2171 82/1 Autografts Cell Biology Female Hematology Hematopoietic Stem Cell Transplantation Humans Internal Medicine Life Sciences Male Medicine Medicine & Public Health Multiple myeloma Multiple Myeloma - therapy Neoplasm Recurrence, Local Public Health Retrospective Studies Stem cell transplantation Stem Cells Survival Transplantation Transplantation, Autologous Treatment Outcome |
| title | Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T05%3A14%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Autologous%20hematopoietic%20cell%20transplantation%20for%20relapsed%20multiple%20myeloma%20performed%20with%20cells%20procured%20after%20previous%20transplantation%E2%80%93study%20on%20behalf%20of%20CMWP%20of%20the%20EBMT&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Drozd-Soko%C5%82owska,%20Joanna&rft.date=2022-04-01&rft.volume=57&rft.issue=4&rft.spage=633&rft.epage=640&rft.pages=633-640&rft.issn=0268-3369&rft.eissn=1476-5365&rft_id=info:doi/10.1038/s41409-022-01592-y&rft_dat=%3Cproquest_pubme%3E2629380008%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2648326338&rft_id=info:pmid/35169284&rfr_iscdi=true |